Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.23 USD
+0.60 (7.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
VIR 8.23 +0.60(7.86%)
Will VIR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VIR
What Makes Vir Biotechnology (VIR) a New Buy Stock
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
Other News for VIR
Vir Biotechnology Announces CFO Departure and Board Expansion
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Vir Biotechnology CEO sells 72,995 common shares